Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial)

202412 citationsJournal Articlehybrid Open Access

Authors

Adrienne G. Waks · Harvard University

Emily Chen · Brigham and Women's Hospital

Noah Graham · Dana-Farber Cancer Institute

Anna Frey · Harvard University

Kenneth Almeida · Dana-Farber Cancer Institute

Victoria Attaya · Dana-Farber Cancer Institute

Cari Ryding ·

Abstract

SC administration of HP shortened patient time burden by approximately 1 hour. SC drug administration can facilitate faster workflows for health care professionals and improve patients' breast cancer treatment experience.

Topics & Keywords

HER2/EGFR in Cancer Research Monoclonal and Polyclonal Antibodies Research Cancer Treatment and Pharmacology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JCO Oncology Practice

Volume 21, Issue 3, pp. 351-357

DOI: 10.1200/op.24.00021

Field-Weighted Citation Impact: 3.36